arrow
A

Anne M. May

Netherlands Cancer Institute
H指数:69
被引数:1.9万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Safety and feasibility of S-1 after capecitabine-induced toxicity in the adjuvant treatment of colon cancer patients: a population-based real-world study

S-1在结肠癌患者辅助治疗中,继发于卡培他滨诱导性毒性后的安全性与可行性:一项基于人群的真实世界研究

2026-02-170
PRE
Effects of personalized live-remote exercise for individuals living beyond primary curative cancer treatment: study protocol for a multinational, super umbrella randomized controlled trial (LION-RCT)

个性化远程现场运动对完成初次治愈性癌症治疗个体的影响:一项跨国超级伞形随机对照试验(LION-RCT)的研究方案

2025-11-240
OA
Prognostic Value of Circulating Tumor DNA for Recurrence and Survival in Patients Undergoing Local Treatment for Initially Unresectable RAS/RAF Mutated Colorectal Cancer Liver Metastases

循环肿瘤DNA对接受局部治疗的初始不可切除的RAS/RAF突变结直肠癌肝转移患者复发和生存的预测价值

2025-11-140
PRE
Pre- and post-diagnostic meat intake in relation to risk of recurrence and mortality among individuals with stage I–III colorectal cancer

确诊前后的肉类摄入与Ⅰ~Ⅲ期结直肠癌患者复发和死亡风险的关系

2025-09-180
OAAI
Factors Associated With Employment and Quality of Working Life in Patients With Metastatic Breast Cancer

与转移性乳腺癌患者就业及工作生活质量相关的因素

2025-07-270
OAAI
Impact of exercise on sexual health, body image, and therapy-related symptoms in women with metastatic breast cancer: The randomized controlled PREFERABLE-EFFECT trial
2025-04-010
OAAI
Experiences of patients with metastatic colorectal cancer participating in a supervised exercise intervention during chemotherapy

接受化疗的转移性结直肠癌患者参与有监督运动干预的体验

2025-01-080
OA
Corticosteroids and other immunosuppressants for immune-related adverse events and checkpoint inhibitor effectiveness in melanoma
2024-08-014
PRE
Supervised, structured and individualized exercise in metastatic breast cancer: a randomized controlled trial
2024-07-252
OAAI
Effects of a structured and individualized exercise program on fatigue and health-related quality of life in patients with metastatic breast cancer: the multinational randomized controlled PREFERABLE-EFFECT study
2024-05-020
PRE